Dr Laura Periman, MD illustrates the current risk factors and prevalence regarding patients with dry eye disease.
Management of Dry Eye Disease
Quality-of-life concerns, including biopsychosocial impacts caused by dry eye disease, are explored by Dr Periman.
Dr Periman addresses cost-related concerns associated with treating dry eye disease.
Various treatments for dry eye disease are navigated with regard to both payer and provider considerations.
Dr Laura Periman introduces current and upcoming pharmacological treatment options, including nasal varenicline, for patients with dry eye disease.
Dr Periman provides final thoughts exploring unmet clinical needs as well as forthcoming innovative opportunities in dry eye disease treatment.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What IRA drug prices will mean for PBMs, health plans and patients
2
Catheter ablation shows benefits for patients with both aFib and sleep apnea
3
Ultra-processed foods linked to early-onset colorectal adenomas in women
4
Biosimilar competition could surpass IRA-negotiated savings by year three
5
